Protein C News and Research

RSS

ImmunoLin provides immediate benefit to the function of immune system and gut

A new study provides evidence that ImmunoLin®, an all natural and GRAS approved source of immunoglobulin, will provide immediate benefit to the function of the immune system and the gut. Immunoglobulins, or antibodies, are specialized proteins found in blood that the immune system naturally produces for immunity.

6 Nov 2009

Prevalence of lactose intolerance may be far lower than previously estimated, says study

Prevalence of lactose intolerance may be far lower than previously estimated, according to a study in the latest issue of Nutrition Today. The study, which uses data from a national sample of three ethnic groups, reveals that the overall prevalence rate of self-reported lactose intolerance is 12 percent - with 7.72 percent of European Americans, 10.05 percent of Hispanic Americans and 19.5 percent of African Americans who consider themselves lactose intolerant.

6 Nov 2009

Scientists identify new behavioral traits of immune cells; findings may help in understanding complex diseases

In diseases such as multiple sclerosis, cells of the immune system infiltrate the brain tissue, where they cause immense damage. For many years, it was an enigma as to how these cells can escape from the bloodstream. This is no trivial feat, given that specialized blood vessels act as a barrier between the nervous system and the bloodstream.

6 Nov 2009

Bortezomib lymphoma drug may be effective against bone cancer in children and teens: Study

A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer.

5 Nov 2009

Althea Technologies offers formulation development services

Althea Technologies, Inc., a leading provider of development and manufacturing services for biopharmaceutical products announced the addition of customized Formulation Development to the company's platform of services, which will be overseen by the newly appointed Dr. James Matsuura, Director of Formulation Development.

5 Nov 2009

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the third quarter ending September 30, 2009.

5 Nov 2009

FDA grants Abraxis BioScience orphan drug designation for ABRAXANE

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug designation to the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of pancreatic cancer as well as stage IIB-IV melanoma.

5 Nov 2009

ARIAD Pharmaceuticals' SUCCEED trial of oral ridaforolimus on track

ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009 and provided an update on corporate developments.

5 Nov 2009

Dietary options and better detection improve food allergy management procedures

Less restrictive dietary options, better detection, targeted avoidance measures, educational directives and potential new therapies are improving food allergy management and giving hope to the more than 12 million Americans affected according to experts at the thirteenth international food allergy conference held during the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Miami Beach, Fla.

5 Nov 2009

ArQule reports financial results for the fiscal quarter and nine months ended September 30, 2009

ArQule, Inc. today reported its results of operations for the fiscal quarter and nine months ended September 30, 2009.

5 Nov 2009

Second-quarter fiscal 2010 results announced by Repligen

Repligen Corporation today reported results for the second quarter of fiscal year 2010, ended September 30, 2009. Total revenue for the quarter was $5,421,000 compared to total revenue of $5,090,000 for the second quarter of fiscal year 2009 ended September 30, 2008.

5 Nov 2009

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi.

5 Nov 2009

Aureus Pharma to provide new AurSCOPE knowledge databases for sanofi-aventis’ R&D division

Aureus Pharma, a leading provider of knowledge management solutions to accelerate discovery in the life sciences industry, announces today the extension of its knowledge database agreement with sanofi-aventis research & development for an additional three-year term.

5 Nov 2009

NIST researchers to develop a certified reference material to assess C-reactive protein

Searching for a needle in a haystack may seem futile, but it's worth it if the needle is a hard-to-detect protein that may identify a person at high risk of a heart attack circulating within a haystack of human serum (liquid component of blood).

5 Nov 2009

Abraxis Health dedicates its new manufacturing facility in Phoenix

Abraxis Health, a fully-integrated personalized healthcare division of Abraxis BioScience, Inc., today announced the dedication of its new manufacturing facility in Phoenix, Arizona. The state of the art biopharma manufacturing plant represents a $70 million investment by LA-based Abraxis, and will create up to 200 high tech jobs.

5 Nov 2009

Scientists identify a novel cellular source of atrial fibrillation

While studying how the heart is formed, scientists at the University of Pennsylvania School of Medicine serendipitously found a novel cellular source of atrial fibrillation (AF), the most common type of abnormal heart beat.

5 Nov 2009

Scientists differentiate human embryonic stem cells into lung epithelial tissue using air-liquid interface

Scientists in Belgium have successfully differentiated human embryonic stem cells (hESC) into major cell types of lung epithelial tissue using a convenient air-liquid interface.

5 Nov 2009

Study demonstrates potential of human Serum Amyloid P to block very aggressive fibrotic pathology

Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today the publication of results from preclinical studies demonstrating that human Serum Amyloid P (hSAP) potently inhibited fibrosis in two independent model systems of kidney fibrosis.

5 Nov 2009

NIH grant to develop a new method for rapidly screening blood samples for biomarkers

Dr. Jennifer Brodbelt, professor of chemistry and biochemistry at The University of Texas at Austin, has received a $734,068 grant from the National Institutes of Health (NIH) to develop a new method for rapidly screening blood samples for biomarkers.

5 Nov 2009

Herbalife establishes new business in Vietnam; Paraguay operations set to begin shortly

Herbalife Ltd., a global nutrition and direct-selling company, announced that it has begun operations in Vietnam, making this the 71st country where the company conducts business. On November 16, operations will begin in Paraguay.

5 Nov 2009

Protein C News and Research

ImmunoLin provides immediate benefit to the function of immune system and gut

Prevalence of lactose intolerance may be far lower than previously estimated, says study

Scientists identify new behavioral traits of immune cells; findings may help in understanding complex diseases

Bortezomib lymphoma drug may be effective against bone cancer in children and teens: Study

Althea Technologies offers formulation development services

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

FDA grants Abraxis BioScience orphan drug designation for ABRAXANE

ARIAD Pharmaceuticals' SUCCEED trial of oral ridaforolimus on track

Dietary options and better detection improve food allergy management procedures

ArQule reports financial results for the fiscal quarter and nine months ended September 30, 2009

Second-quarter fiscal 2010 results announced by Repligen

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Aureus Pharma to provide new AurSCOPE knowledge databases for sanofi-aventis’ R&D division

NIST researchers to develop a certified reference material to assess C-reactive protein

Abraxis Health dedicates its new manufacturing facility in Phoenix

Scientists identify a novel cellular source of atrial fibrillation

Scientists differentiate human embryonic stem cells into lung epithelial tissue using air-liquid interface

Study demonstrates potential of human Serum Amyloid P to block very aggressive fibrotic pathology

NIH grant to develop a new method for rapidly screening blood samples for biomarkers

Herbalife establishes new business in Vietnam; Paraguay operations set to begin shortly

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News